Image source: The Motley Fool.

Date

Wednesday, Aug. 6, 2025, at 4:30 p.m. ET

Call participants

  • Chief Executive Officer and Chair of the Board — Omid Farokhzad
  • Chief Financial Officer and President — David Horn

Need a quote from a Motley Fool analyst? Email [email protected]

Risks

  • Management noted that "Near-term macro pressures, including evolving tariffs implementation, and continued uncertainty around government funding, are likely to weigh on market visibility through year-end."
  • David Horn stated that continued pressure on customer CapEx budgets and elongated sales cycles are impacting new instrument purchases.
  • Guidance assumes customers will "continue to face headwinds from budget constraints, ongoing uncertainty around government funding, particularly related to the NIH, and broader macroeconomic volatility,"
  • Any changes in academic or government funding may impact academic customers' ability to make purchases, as this channel remains about 30% of 2025 revenue exposure.

Takeaways

  • Total Revenue -- $4.1 million in Q2 2025, up 32% year-over-year, driven primarily by higher product and service sales.
  • Product Revenue-- $2.7 million, driven by shipments of Proteograph instruments and consumable kits.
  • Service Revenue-- $1.2 million, including $409,000 of related party revenue, reflecting continued demand for STAC service projects.
  • Gross Margin-- 52%, compared to 56% in Q2 2024, with the decrease attributed to increased instrument installation and training costs.
  • Operating Expenses-- $22.6 million, down 21% from $28.8 million, mainly due to lower stock-based compensation and professional services costs.
  • Net Loss -- $19.4 million in Q2 2025, narrowing from $22.9 million in the prior year.
  • Free Cash Flow Loss(non-GAAP, defined as net cash used in operating activities less purchases of property and equipment) -- $27.3 million for the six months ended June 30, 2025, with full-year 2025 guidance unchanged at $40 million to $45 million.
  • Cash, Cash Equivalents, and Investments-- $263.3 million at period end, with management expressing confidence that these resources are "sufficient capital to reach cash flow breakeven."
  • Share Repurchases-- 10.7 million Class A common shares bought back at a VWAP of $1.86, reflecting $20 million utilized from a $25 million program and reducing net total shares outstanding by approximately 13% as of June 30, 2025.
  • 2025 Revenue Guidance-- Reiterated at $17 million to $18 million, representing 24% growth at the midpoint, despite ongoing macroeconomic uncertainty.
  • Proteograph One Launch-- More than doubled throughput to over 1,000 samples in 4.5 hours versus the previous XT generation, enabling population-scale studies of up to 20,000 samples.
  • Large-Scale Academic Collaborations-- Announced a 20,000-sample plasma study with Korea University and highlighted ongoing significant contracts, including a previously disclosed 10,000-sample project with Discovery Life Sciences.
  • Third-Party Validation-- 52 customer publications, reviews, and preprints in high-impact journals now reference the Proteograph product suite.
  • STAC Program-- Over half of instrument shipments were to prior STAC customers, reflecting strong conversion from service project users to full platform adoption.
  • Thermo Fisher Partnership-- Sales teams are now fully trained, and initial revenues from this collaboration are expected to be recognized in Q3 2025, with the pipeline described as "growing" by management but revenue to date as "extremely modest."

Summary

Seer(SEER 0.98%) delivered 32% year-over-year revenue growth to $4.1 million in Q2 2025, led by increased product and service sales despite persistent CapEx pressure and customer budget constraints. Collaboration-driven population-scale studies, including a 20,000-sample partnership with Korea University and continued validation through 52 third-party publications, signaled expanding commercial traction and external adoption. Instrument shipments saw a high conversion rate from users of the STAC access model, highlighting operational leverage in customer acquisition and retention strategies. Management maintained full-year 2025 revenue guidance of $17 million to $18 million and noted $263.3 million in cash, cash equivalents, and investments as sufficient to reach cash flow breakeven, all while executing a 13% share reduction through buybacks. Strategic launches, especially the new Proteograph One, more than doubled workflow throughput and positioned Seer at the forefront of unbiased, large-scale proteomics research.

  • The share repurchase program utilized approximately $20 million of its $25 million authorization as of June 30, 2025, lowering shares outstanding and reflecting management's conviction in Seer's valuation.
  • Gross margin declined to 52%, with management attributing the change to increased installation and training costs.
  • David Horn clarified in the Q&A that "most of the revenue is coming from, you know, our own direct sales team as well as some of our population-scale study work," with the Thermo Fisher collaboration pipeline expected to build further revenue in future quarters.
  • Seer continues to support strategic service projects at lower price points to drive additional presentations, publications, and market validation.

Industry glossary

  • Proteograph Product Suite: Seer’s proprietary platform that combines engineered nanoparticles, automated instrumentation, and software for high-throughput, deep, and unbiased proteomics studies.
  • STAC (Seer Technology Access Center): A Seer service program allowing researchers to submit samples for processing and data analysis using the Proteograph platform as a path to in-house adoption.
  • PQTL (Protein Quantitative Trait Loci): Genomic loci that influence the abundance of specific proteins, serving as key molecular phenotype markers in proteogenomics research.
  • SIP (Strategic Instrument Placement Program): A Seer initiative that loans instruments to customers in exchange for upfront consumables purchases to drive adoption amid capital constraints.
  • VWAP (Volume Weighted Average Price): The average stock price, weighted by volume, at which share repurchases were executed within a specified period.

Full Conference Call Transcript

Kelly Gura: Good day, and welcome to the Seer, Inc. Second Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. To withdraw your question, please note this event is being recorded. I would now like to turn the conference over to Kelly Gura, Investor Relations. Please go ahead. Thank you. Earlier today, Seer released financial results for the quarter ended 06/30/2025. If you have not received this news release or if you would like to be added to the company's distribution list, please send an email to [email protected]. In addition, during today's conference call, we will be referencing a slide presentation that can be accessed on the events and presentations of Seer's Investor Relations website.

Joining me today from Seer is Omid Farokhzad, Chief Executive Officer and Chair of the Board, and David Horn, Chief Financial Officer and President. Before we begin, I would like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section titled Forward-Looking Statements in the press release we issued today.

For a more complete list and description, please see the risk section of the company's quarterly report on October for the quarter ended 06/30/2025, and in its other filings with the Securities and Exchange Commission. Except as required by law, Seer disclaims any intention or obligation to update or revise any financial projections or forward-looking statements whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, 08/06/2025. With that, I would like to turn the call over to Omid.

Omid Farokhzad: Thanks, Kelly, and thank you everyone for joining us this afternoon. I will begin our call today by providing updates on our business, and I will then turn the call over to David to provide more details on our financial results for 2025 as well as our outlook for the full year. Beginning with Slide three, Q2 was a pivotal quarter for Seer. As we continue to execute with discipline, advance key commercial and product milestones, and accelerate the validation and impact of our platform. The proteograph product suite is unbiased, meaning it's inherently untargeted, and enables the scientists to view an unprecedented breadth of the proteome from the most abundant proteins to the least abundant proteins.

This deep unbiased proteomics platform is based on our proprietary engineered nanoparticles, which is core to the proteograph product suite. In the second quarter, we launched the proteograph one workflow, announced a landmark 20,000 sample population scale study with Korea University, and continued to build commercial momentum with strong instrument placement and continued traction with our Seer Technology Access Center or STAC. We also saw increased third-party validation through high-impact publications, and compelling data presented at major industry conferences. Back in January, we laid out four core growth catalysts for 2025, and I'm proud to share that we've delivered progress across each one.

We've always believed that our technology would redefine the trajectory of proteomics and make a meaningful impact within the scientific community. We believe our progress in the second quarter is a clear demonstration of this impact. We ended the quarter with $4.1 million of revenue, representing 32% year-over-year growth and a strong balance sheet of approximately $263 million in cash, cash equivalents, and investments. We continue to make highly concentrated and impactful investments in R&D to execute on our product roadmap, and we're continuing our share repurchase program as we believe there is a significant dislocation between our core value proposition and what our stock price reflects today.

As of June 30, we have repurchased approximately 20 million of our Class A common shares under our 25 million share repurchase program that was authorized in May 2024, reducing our net total shares outstanding by approximately 13%. We recognize the policy environment remains fluid, and continue to closely monitor how emerging US policy development may influence our customer base. Near-term macro pressures, including evolving tariffs implementation, and continued uncertainty around government funding, are likely to weigh on market visibility through year-end.

Despite these headwinds our customers are facing, our strong performance in the first half of the year gives us confidence to reiterate our full year 2025 revenue guidance of $17 to $18 million, representing 24% year-over-year growth at the midpoint. Now I'd like to walk through our recent progress in our core initiatives of validating our platform, enhancing access, driving innovation, and enabling larger cohort studies in more detail. Starting with product innovation on slide four, this quarter marked a major inflection point for Seer with the launch of our high throughput proteograph one assay SP200 automation instrument. This is a transformative step forward, not just for Seer, but for the entire field of proteomics.

Our vision is to enable deep and balanced proteomics research at scale, and with this launch, we're empowering researchers to move from poorly powered small studies that may not replicate to larger cohort studies that are adequately powered. With the proteograph one, we've more than doubled throughput to over a thousand samples in approximately four and a half hours compared to proteograph XT. The proteograph one enables the identification of up to 10 times more proteins than traditional mass spec workflows, achieving industry-defining precision. In addition to the performance improvements, we believe our customers could achieve a meaningful reduction in cost per sample for the full workflow.

As evidenced by the initiation of multiple large-scale studies that I will expand on shortly, the combination of proteograph one attributes is translating to an increase in the size of the studies that our customers are running, which we believe will be an important catalyst for revenue growth. We also recently launched the proteograph direct assay enabling customers to run cell and tissue samples on our SP200 instrument. This assay was introduced in response to the strong demand from customers to use our automated instrumentation and other workflows that don't leverage our proprietary nanoparticles. Proteograph Direct streamlines sample prep by drastically reducing manual processing times to just sixty minutes for AV samples without compromising depth or reproducibility.

Looking ahead, we plan to continue broadening our menu, expanding the capabilities of our platform, and innovating on our workflow to provide the best solutions for our customers. Now moving on to larger cohort studies on slide five. Over the last three years, Seer has helped redefine deep unbiased proteomics by enabling researchers to move from small-scale studies of tens of samples to those involving up to tens of thousands of samples, which were previously only possible using targeted proteomics approaches. This quarter, we announced a landmark population scale study in collaboration with Korea University representing the largest deep plasma proteomic study of its kind.

This three-year study intends to identify novel blood-based biomarkers for young adults in their twenties and thirties using samples from 15,000 cancer patients and 5,000 healthy subjects sourced from Korea's leading cancer institutions. Powered by our newly launched proteograph one assay, the SP200 automation instrument, and Thermo Fisher's Orbitrap Astral Mass Spectrometer, this is the first large-scale plasma proteomic study to leverage mass spectrometry and AI-driven analytics for early cancer detection. Korea University selected our platform for its unique ability to deliver the depth, scale, and reproducibility required for such an ambitious study.

This collaboration highlights our belief that the proteograph is unlocking the next generation of sensitive, scalable, and personalized diagnostics, laying the foundation for earlier interventions and improved outcomes in young adult cancer patients worldwide. Importantly, this follows our announcement on our last earnings call that Discovery Life Sciences, one of our centers of excellence and a leading omics service provider, in collaboration with us secured a significant contract from a new customer to run a 10,000 sample study on the proteograph product suite and the Orbitrap Astral Mass Spectrometer. Taken together, population scale studies demonstrate our belief that Seer is uniquely positioned as the only truly unbiased, scalable, and deep proteomics platform to power the next generation of proteomic discovery.

We expect to see a growing number of population scale studies in the near term. Moving on to the validation of our platform on slide six. Validation of our technology continues to grow, with 52 customer publications, preprints, and reviews, many in high-impact journals highlighting the unique capabilities of the proteograph product suite. This adds to hundreds of abstracts, presentations, and talks showcasing our platform's differentiated biological insights. At recent industry conferences, an increasing number of studies further demonstrated the proteograph's ability to generate unique biological insights.

At the American Society for Mass Spectrometry or ASMS, our customers, collaborators, and Seer scientists unveiled new data generated from the proteograph across 14 poster presentations, and multiple researchers presented compelling findings from their early access experience with the recently launched proteograph one workflow. Now turning to slide seven. At ASMS, Dr. Gedi Patti, a professor at Washington University in St. Louis, presented a study using the proteograph one to analyze the plasma proteomes of metabolically healthy lean, metabolically healthy obese, and metabolically unhealthy obese individuals. Identified distinct protein signatures in the metabolically healthy obese population, including three novel biologically relevant protein biomarkers undetectable by an affinity-based assay.

These biomarkers suggested that metabolically healthy obese individuals may buffer oxidative stress better, regulate their glucose levels better, and clear more lipids from the plasma compared to the other two cohorts. Though a small study, it highlights the proteograph one's ability to uncover novel biology and advance metabolic disease research. Dr. Josh Kuhn, professor at the University of Wisconsin Madison, presented his findings from the pilot study that validated the high performance of the proteograph one workflow on monkey samples, delivering a meaningful increase in the amount of unique protein groups versus NEAT methods. Turning to slide eight. At the third annual symposium on human proteome and health in Oxford, in June, Dr. Claudia Langenberg and Dr.

Mike Pysner from Queen University of London presented compelling data from 1,500 individuals in the genes and health cohort run under proteograph XT. We believe there are three key takeaways from the proteogenomic study that highlight the power of the proteograph platform. First, the proteograph detected a high number of proteins previously not found using affinity-based methods. Out of the more than 8,000 proteins detected in plasma, over 2,300 of these proteins represented a, quote, previously unexplored proteome, unquote, according to study lead Dr. Mike Pysner. Second, the proteograph detected a high number of protein quantitative trait loci, or PQTLs, that were previously not found by affinity-based technologies.

Over 1,200 PQTLs were detected with over half of them not detected to date by studies up to 40 times larger. The proteograph detected 140 of these novel PQTLs in proteins that were measured by affinity-based methods. However, the PQTLs were not detected by these technologies from phenotype-wide association studies or PheWAS. Third, the proteograph uniquely confirmed the absence of some proteins in plasma that had lost their function. These findings demonstrate the proteograph's ability to generate meaningful biological insights through its superior depth and unbiased approach. Most recently highlighted by Drs. Claudia Langenberg and Mike Pysner in the Genome Web Webinar.

We continue to partner with leading investigators and host webinars that showcase how researchers are using our platform to generate novel biological insights, further strengthening our growing body of evidence and reinforcing Seer as a trusted partner in the proteomics community. Now moving to slide nine, to take a closer look at the progress with accelerating access to the proteograph product suite. We continue to see strong demand for STAC, which lowers the barrier of adoption of the proteograph product suite. STAC allows a proteograph user to run samples in their own lab and have Seer run the mass spec, or alternatively, provides end-to-end services from sample to proteomics data and analysis.

In Q2, over half of our instrument shipments were acquired by customers who have previously accessed our STAC, representing another solid quarter of STAC to instrument conversion. STAC remains a strong revenue contributor and a strategic asset, giving users hands-on experience with the proteograph and in some cases, leading to in-house instrument adoption. With the increased throughput enabled by the proteograph one workflow, we have expanded STAC's capacity to meet a growing number of demands without additional investments. We look forward to serving more customers as they generate critical data for their ongoing studies. Our strategic instrument placement program or SIP remains a key driver of adoption.

By leveraging available operating budgets, SIP helps capital-constrained customers, particularly in the current macroeconomic environment, access our technology. Under this program, we loan an instrument to a customer with an upfront purchase of a consumable kit. Our expanded partnership with Thermo Fisher Scientific to co-market and sell the proteograph product suite alongside the Orbitrap Astral Mass Spectrometer has been progressing well. This powerful pairing enables population-scale deep unbiased proteomics for the first time with exceptional robustness and reproducibility. In addition, this partnership further strengthens our commercial reach and makes it easier for our customers to access a seamless end-to-end solution for unbiased proteomics.

We've completed training across Thermo Fisher's US and European sales forces, and are beginning to see this partnership translate into advanced stage opportunities. We continue to see traction in several regions, and we are actively pursuing additional population-scale opportunities together. Reinforcing our confidence in the ability of this partnership to drive adoption. I'm deeply proud of the team's execution this quarter as we lay a strong foundation for the rest of the year and beyond. With that, I will now turn the call over to David.

David Horn: Thanks, Omid. Turning to slide 10. Total revenue for 2025 was $4.1 million, representing an increase of 32% compared to $3.1 million in 2024 and was primarily due to higher product and service revenue. Revenue recognized primarily consisted of sales of proteograph instruments, consumable kits, and service revenue. Product revenue for the second quarter of 2025 was $2.7 million and consisted of sales of proteograph instruments and consumable kits. We were pleased by the traction we saw in terms of instrument shipments and the purchase of consumable kits in the quarter, despite the continued pressure we are seeing on CapEx budgets, and elongated sales cycles for the outright purchase of new instruments.

Service revenue was $1.2 million for 2025, including $409,000 of related party revenue, and primarily consisted of revenue related to STAC service projects. We remain encouraged by the strong customer interest in running projects through STAC, particularly as more users gain access to proteograph data. Sample volumes increased again this quarter on a year-over-year basis. We may continue to support projects for key strategic studies and marketing initiatives that will result in additional presentations and publications in the near term. These efforts, while impactful, are offered at lower price points than our typical STAC service projects. Other revenue was $119,000 for 2025, consisting of leasing and shipping revenue.

Total gross profit was $2.1 million for the second quarter of 2025, representing a gross margin of 52%, compared to $1.7 million in 2024, representing a gross margin of 56%. Gross margins were driven by higher consumable and service revenue in 2025, offset by an increase in instrument installation and training costs relative to 2024. We continue to expect variability in our gross margin on a quarter-by-quarter basis, since the proportion of instrument, consumable, and service revenue fluctuates in any given quarter. At scale, we continue to believe our long-term gross margins will be in the range of 70% to 75%.

Total operating expenses for the second quarter of 2025 were $22.6 million, including $3.7 million of stock-based compensation, a decrease of 21% compared to $28.8 million, including $7.3 million of stock-based compensation in 2024. Research and development expenses for 2025 were $12 million, a decrease of 6% compared to $12.7 million in 2024. The decrease in R&D expenses was primarily due to decreases in stock-based compensation and allocated costs. Selling, general, and administrative expenses for 2025 were $10.7 million, a decrease of 34% compared to $16.1 million in 2024. The decrease in SG&A expenses was primarily due to a decrease in stock-based compensation and professional services expenses. Net loss for 2025 was $19.4 million compared to $22.9 million in 2024.

Free cash flow loss, defined as net cash used in operating activities in the period less purchases of property and equipment in the period, was approximately $27.3 million for the quarter ended 06/30/2025. We continue to expect free cash flow loss to be in the range of $40 million to $45 million for the year. In addition, we continued our share repurchase activities in 2025. We continue to believe that there is a significant dislocation in our share price. In the second quarter, we repurchased approximately 3.9 million Class A common shares at an average price of $1.92 per share.

As of June 30, we have repurchased approximately 10.7 million Class A common shares at a VWAP of $1.86 per share, utilizing approximately $20 million of our $25 million share repurchase program authorized in May 2024. As a result, we have reduced our net total shares outstanding by approximately 13%. We ended the quarter with approximately $263.3 million in cash, cash equivalents, and investments. Importantly, we believe that with our current cash, cash equivalents, and investments on hand, we have sufficient capital to reach cash flow breakeven. Turning now to our outlook for the year on slide 11.

We continue to expect revenue to be in the range of $17 million to $18 million for 2025, representing growth of 24% at the midpoint over the full year 2024. Our guidance range reflects the assumption that our customers will continue to face headwinds from budget constraints, ongoing uncertainty around government funding, particularly related to the NIH, and broader macroeconomic volatility, including potential tariffs. In 2025, we believe we will have approximately the same exposure to academic and government entities in terms of our overall revenue as in the range of 30% in 2024. In 2025, the majority of our academic and government revenue has come from academic customers.

Any changes in their funding may impact their ability to make purchases in 2025. Tariff and most favored nation pricing proposals, which would affect pharmaceutical companies, have introduced uncertainty for our commercial customers, with the full impact yet to be determined. We were encouraged by our results in the second quarter with launches of new products in multiple population-scale studies powered by the proteograph, increased third-party validation through compelling data, and strong instrument shipments. That said, we also saw some customers delaying purchases amid this backdrop. As such, we remain cautious given this macro uncertainty, but are reaffirming our revenue guidance at this time. At this point, I would like to turn the call back to Omid for closing comments.

Omid Farokhzad: Thank you, David. Moving on to Slide 12. I'm proud of our team's execution in the second quarter as we brought new products to market and drove deep unbiased population-scale studies in plasma, which were not possible before Seer. We are operating in a challenging and dynamic macro environment, yet we continue to position ourselves for strength ahead. We remain focused on advancing our four key growth drivers in 2025, and I look forward to keeping you updated on our progress. With that, we will now open it up for questions. Operator?

Operator: We will now begin the question and answer session. To ask a question, you may press star then 1 on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble our roster.

David Horn: Prior to our first question, I just wanted to clarify one comment in my prepared remarks. Free cash flow loss of $27.3 million is for the six months ended 06/30/2025, rather than the quarter ended June 30.

Operator: Our first question comes from Dan Brennan with Cowen. Please go ahead.

Kyle (for Dan Brennan): Hey, good afternoon, guys. This is Kyle on for Dan. Thanks for taking the questions. I guess maybe to start, can you share any early feedback you're getting on the new proteograph one assay? I guess, what's the uptake in usage looking like so far in that new assay?

Omid Farokhzad: Yeah, Kyle. Thank you. As you know, we launched the proteograph one assay and the high throughput SP200 automation instrument at the ASMS in June. It was an important inflection point for us because it became possible for customers to do very, very large-scale studies. It doubled the throughput, reduced the assay run time on the instrument to about four and a half hours, so it could easily fit within an eight-hour workday. And then the precision is excellent, and you could run 80 samples at once in a four and a half hour run. And because the assay went from two mass spec injections per sample to one, it also then increased the throughput on the mass spec side.

The feedback that we've received so far, Kyle, has been fantastic. KOLs love it. We had done early access of the instrument to some KOLs, and they did present some data at the ASMS, and the data was great. And then importantly, because of the enhanced throughput, this is now enabling large-scale population-scale studies to be done with the mass spec. And, of course, you heard that we had done the DLS study that was 10,000 samples. And then we just announced also the ASMS a 20,000 sample study with Korea University. And there's other population-scale studies that are on the launch pad, Kyle, and none of it would be possible if we had not increased throughput.

So the feedback has been great. And the impact of it is already becoming evident.

Kyle (for Dan Brennan): Got it. Thanks. And then maybe just moving over to STAC. You know, it seems like that's really starting to bear some fruit here. You mentioned half of the instruments you placed in the quarter were from customers that had used the STAC program. Can you discuss your pipeline of potential customers currently using the STAC program? You know, but are an opportunity to place an instrument, you know, in-house? I guess as a percentage of your expected placements for the rest of the year, you know, how many of these do you think are coming from these STAC customers versus, you know, otherwise?

David Horn: Kyle, it's David. Thanks for the question. Yeah, right. STAC continues to be a great pipeline for placing instruments and as well as the SIP program as well. So the two together kind of work really well. You know, hard to quantify. I think, you know, if you look at the first half of the year, it certainly was the majority of shipments were former STAC customers. So I think as STAC continues to build, we get new customers, you know, taking our first step through the STAC, doing a project, and then, you know, wanting to bring the technology in-house. I think we'll continue to see the benefits.

I think we'll continue to see, you know, strong benefit of having that STAC, you know, most of our customers have first experienced the technology through a STAC project.

Kyle (for Dan Brennan): Got it. Thank you.

Operator: Our next question comes from Rachel Vatnsdal with JPMorgan. Please go ahead.

Jaden Rismay (for Rachel Vatnsdal): Hi. This is Jaden on for Rachel. So my first question is regarding your co-marketing partnership with Thermo. Could you provide a little bit more insight on how much revenue is attributed to this partnership? Compared to other sources such as your large-scale study revenues? And then how meaningful do you expect this partnership and program to become for you in the near future?

David Horn: Yeah. Thanks, Jaden. I think we're continuing to see a lot of benefits from the Thermo partnership. As Omid mentioned in his prepared remarks, not only from a population-scale study perspective but also active opportunities. I can say that we have seen some of those opportunities come to fruition. But I will say that the revenue is still extremely modest. So again, I think we'll continue to see that probably pick up in the back half of the year. But to date, it's been very modest. Remember, we only fully trained the Salesforce at the end of the first quarter, beginning of the second quarter. And then it's been rolling out globally for them.

So it's kind of right on the time frame we expected. And so, again, I think we'll continue to see that momentum build. But most of the revenue is coming from, you know, our own direct sales team as well as some of our population-scale study work that we're doing. And so, again, I think we'll continue to see both our own direct efforts as well as the efforts with Thermo drive revenues in the second half.

Omid Farokhzad: I would just add. I mean, I think you can expect that, for example, in Q3, we will begin to recognize the first revenue from the collaboration come to fruition. But, importantly, the pipeline of their opportunities, remember, they've been only at it for less than a quarter. It's growing, so I'm very encouraged by that. But we are being cautious and modest in terms of our assumption for the guide for the year. But I do expect the first revenue from the collaboration to come to fruition this quarter.

Jaden Rismay: Okay. Yeah. That's perfect. And then just on competition, could you discuss the competitive landscape regarding customers choosing to use your technology? In a research setting compared to other existing proteomic technologies? That might be more aligned with a biased proteomic method just given that the space has seen more interest from other companies within the past year?

Omid Farokhzad: Yeah. Of course. Look. I think you look at the competitive landscape at a very high level, I always frame them into three buckets. So those that consider a mass spec not to be a good detector, and therefore, they're developing their own novel detector, you know, that includes Quantum SI, Nautilus, on the public side, Arista and Encodi on the private side. And then there's a targeted one, you know them all too well. On the public side, Soma. OLINK, now part of Thermo, and then maybe Quanterix on the private side, Alamar. And then there is, you know, unbiased proteomic and scale. And I think Seer uniquely sits in that space, and that's the space that we pioneered.

That's the space that we've continued to execute on, and that's the space that is now allowing large-scale studies to be done. Now we are relatively new to this game because technologies like Soma or OLink have been around for many, many years in the case of Soma. Almost twenty plus years and OLINK, ten or fifteen years, Seer is relatively new, and so the publications and the customer validations are just emerging. Now before Seer, it was just not possible to do large-scale studies. And so biobanks and any investigator that needed to do large-scale studies were forced to use the only available tool to them at the time, which was a targeted approach. And so those technologies scaled.

Seer fundamentally changed the arc of proteomics making unbiased proteomics, deep unbiased proteomics, scalable. Before Seer, the largest deep unbiased proteomic that was published was a study of 48 samples. And the deepest study, by the way, from Broad Institute was on a study of 16 samples that went to a depth of about 4,500 proteins. We've now had in just in 2025, just the first half of the year, multiple customers that are now doing large-scale studies, and by that, I mean, 10,000 plus. So this Korea University one that we announced is 20,000 samples. There are other studies of that scale that are on the launch pad, and we're in discussions with them.

And by the way, this followed the Q1 announcement of the Discovery Life Sciences 10,000 sample study with a customer. So now it changed. And it changed not because we could scale, but also in terms of our improvements cost went down, depth went up, throughput went up, mass spec utilization time went down. So it's a confluence of a lot of innovation that we worked on and collaborated with our colleagues that now makes it completely possible to do large-scale studies in an unbiased way with proteomics.

And now the question is, if you're a customer and you can spend your dollars in a targeted way where the discovery potential is very limited or in an untargeted or in an unbiased way where the discovery potential is unlimited, which one do you choose? I think the evidence is that customers are leaning toward the untargeted, unbiased. This is not to say that targeted approaches are not good. I actually think they're very complementary. No different than the way arrays were when next-generation sequencing came about. I think targeted approaches are excellent. When you know what you're looking for, in small panels, for example, like the Alamar technology or some of the smaller OLink platforms or kits.

But when you're looking for large content, and you're looking for discovery, the only way to do it and to do it well and to do it effectively is to do it in an untargeted way. So I think we are just at the very, very beginning of this massive content generation that is going to be enabled by Seer. Over the course of the very near term and the coming years.

Operator: This concludes our question and answer session. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.